-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Qksk7Ds4V5ZqSetZMdJkEZAvVORYf1H42AI+baxyLTODNveWZhUCvlLnmqRqW5iv neLhaG6z5LZOQfZXqbOoBg== 0001188112-09-000647.txt : 20090323 0001188112-09-000647.hdr.sgml : 20090323 20090323083637 ACCESSION NUMBER: 0001188112-09-000647 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090318 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20090323 DATE AS OF CHANGE: 20090323 FILER: COMPANY DATA: COMPANY CONFORMED NAME: THERAGENICS CORP CENTRAL INDEX KEY: 0000795551 STANDARD INDUSTRIAL CLASSIFICATION: INSTRUMENTS FOR MEAS & TESTING OF ELECTRICITY & ELEC SIGNALS [3825] IRS NUMBER: 581528626 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14339 FILM NUMBER: 09697539 BUSINESS ADDRESS: STREET 1: 5203 BRISTOL INDUSTRIAL WAY CITY: BUFORD STATE: GA ZIP: 30518 BUSINESS PHONE: 7702710233 MAIL ADDRESS: STREET 1: 5203 BRISTOL INDUSTRIAL WAY CITY: BUFORD STATE: GA ZIP: 30518 FORMER COMPANY: FORMER CONFORMED NAME: NUCLEAR MEDICINE INC DATE OF NAME CHANGE: 19860902 8-K 1 t64892_8k.htm FORM 8-K t64892_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 8-K
 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 18, 2009

THERAGENICS CORPORATION®
(Exact name of registrant as specified in charter)


Delaware
000-15443
58-1528626
(State of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)

5203 Bristol Industrial Way
Buford, Georgia 30518
(Address of principal executive offices / Zip Code)


(770) 271-0233
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
  o
Written communications pursuant to Rule 425 under the Securities Act.
     
  o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
     
  o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
     
  o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
 
 
 
 
 
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On March 18, 2009, Theragenics Corporation (the "Company") received a letter from the New York Stock Exchange (the "NYSE") notifying the Company that it no longer satisfies one of the NYSE’s standards for continued listing.  Pursuant to NYSE Rule 802.01B, a listed company must maintain shareholders’ equity of at least $75 million if the company’s average market capitalization has been below $75 million for over the last thirty trading days.  The impairment charges and resulting net loss previously reported for the fiscal year ended December 31, 2008 reduced the Company’s stockholders’ equity to $74.1 million, and the Company’s average global market capitalization for the past thirty trading days has been below $75 million.  Under the applicable NYSE procedures, the Company has forty-five days from the receipt of such notice to submit a cure plan to the NYSE.  This plan must demonstrate the Company’s ability to achieve compliance with the continued listing standards within the next eighteen months.  The Company intends to submit a plan that will demonstrate compliance with the listing standard related to maintaining stockholders’ equity of at least $75 million within the required time frame.

 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
By:
/s/    M. Christine Jacobs        
  
   
M. Christine Jacobs
  
   
Chief Executive Officer
  
 
Date: March 23, 2009
 
 
 
3
 -----END PRIVACY-ENHANCED MESSAGE-----